Infant Bacterial Therapeutics is developing the pharmaceutical drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC) in premature infants.

IBP-9414
Read more about IBP-9414 mechanism of action here
Read more about previous clinical literature here

Read more about the Safety and Tolerability trial through the Hot Topics poster